Matters
- Represented NewLeaf Symbiotics, Inc., a pioneer and global leader of pink-pigmented facultative methylotrophs (PPFMs), on its $45 million Series D financing.
- Reorganization and combination of three medical supply companies
- Sale of an agricultural biological products company to a multinational agricultural and chemical company
- Initial public offerings for companies in the tissue paper and in the commercial aviation industries
- Series of bolt-on acquisitions for a private equity-owned medical device company
- Acquisition of a soybean seed company focused on developing and selling high protein and high oleic oil soybeans
- Sale of the assets of a division of a publicly traded electronics components distributor
- Series C preferred stock and royalty interests financing for a venture capital-backed pharmaceutical discovery company
- Acquisition of a global biological products company based in Australia
- Series of early-stage venture capital investment for a multinational agricultural company
- Shelf registration and take-down offerings for an industrial equipment company
- Engagement letters, fairness opinions and proxy disclosure for a national investment bank
